Sera Prognostics to Announce Q4 and FY 2025 Financial Results
- Earnings Release Schedule: Sera Prognostics will report its Q4 and FY 2025 financial results on March 18, 2026, after market close, which is expected to positively influence investor confidence.
- Conference Call Details: The company will host a conference call at 5:00 PM ET on the same day to discuss financial results and operational highlights, enhancing transparency and attracting more investor interest.
- Innovative Testing Product: Sera's PreTRM® Test is the only broadly validated blood-based biomarker test that provides early, individualized risk predictions for spontaneous preterm birth during weeks 18 to 20 of pregnancy, enabling more informed clinical decisions by physicians.
- Market Demand Context: The 2025 March of Dimes report indicates persistent poor preterm birth rates in the U.S., affecting newborn health, and Sera's products are poised to improve this situation by providing early intervention information, potentially reducing healthcare costs.
Trade with 70% Backtested Accuracy
Analyst Views on SERA
About SERA
About the author
Sera Prognostics to Announce Q4 and FY 2025 Financial Results
- Earnings Release Schedule: Sera Prognostics will report its Q4 and FY 2025 financial results on March 18, 2026, after market close, which is expected to positively influence investor confidence.
- Conference Call Details: The company will host a conference call at 5:00 PM ET on the same day to discuss financial results and operational highlights, enhancing transparency and attracting more investor interest.
- Innovative Testing Product: Sera's PreTRM® Test is the only broadly validated blood-based biomarker test that provides early, individualized risk predictions for spontaneous preterm birth during weeks 18 to 20 of pregnancy, enabling more informed clinical decisions by physicians.
- Market Demand Context: The 2025 March of Dimes report indicates persistent poor preterm birth rates in the U.S., affecting newborn health, and Sera's products are poised to improve this situation by providing early intervention information, potentially reducing healthcare costs.
Sera Prognostics to Present at TD Cowen Health Care Conference
- Conference Participation: Sera Prognostics will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, in Boston, showcasing the company's latest achievements, which is expected to attract investor attention and enhance the company's market image.
- Innovative Testing: The company's PreTRM® Test is the only broadly validated blood-based biomarker test that predicts the risk of spontaneous preterm birth during weeks 18 to 20 of pregnancy, enabling physicians to make more personalized clinical decisions and improve maternal and neonatal health management.
- Preterm Birth Issue: According to the 2025 March of Dimes Report, the U.S. received a D+ grade for preterm birth for the fourth consecutive year, highlighting the long-term challenges in improving preterm birth rates, with healthcare costs associated with prematurity estimated at $25 billion in 2016, imposing a significant economic burden on society.
- Future Outlook: Sera Prognostics' participation not only demonstrates its leadership in maternal and neonatal health but may also enhance the market acceptance of the PreTRM Test, driving future revenue growth and capital management needs.
Sera Prognostics Launches New Blood Test Significantly Reducing Preterm Birth Risk
- Preterm Risk Screening: The PRIME study demonstrates that among 5,018 women, those identified as high-risk through the PreTRM Test and receiving targeted interventions significantly reduced preterm birth risks and improved neonatal outcomes, highlighting the test's effectiveness in early identification of at-risk pregnancies.
- Intervention Effectiveness: By administering daily vaginal progesterone and low-dose aspirin, the study found that women using the PreTRM Test had a significantly lower NICU admission rate compared to standard care, with approximately 39 women needing to be screened to prevent a single NICU admission.
- Strengthening Clinical Evidence: Zhenya Lindgardt, CEO of Sera Prognostics, noted that the findings not only reinforce the strong results from the AVERT PRETERM Trial but also build a robust clinical evidence base for the PreTRM test-and-treat strategy, driving transformation in maternal and neonatal health.
- Future Outlook: Sera Prognostics aims to enhance maternal and neonatal health outcomes through education and equitable access to prenatal care, anticipating measurable value for patients, providers, and health systems while setting a new commercial and clinical standard.
Biotech Stocks Decline, Sera Prognostics Falls 10.1%
- Market Underperformance: Biotechnology stocks collectively declined by approximately 1.1%, indicating the sector's vulnerability in the current market environment, which could negatively impact investor confidence and lead to capital outflows.
- Individual Stock Drag: Sera Prognostics saw a significant drop of about 10.1%, while Rezolute fell approximately 9.1%, raising concerns about the overall biotech sector and potentially affecting the fundraising capabilities of related companies.
- Industry Trends: The overall weakness in the biotech sector may reflect investor caution regarding the progress of new drug developments, particularly amid increasing economic uncertainties, which could lead to reduced investments within the industry.
- Market Sentiment Impact: As biotech stocks decline, market sentiment may further deteriorate, prompting investors to reassess their investment strategies in the sector, which could affect future capital inflows.
Sera Prognostics (SERA) Price Target Raised by 81.82% to $5.10
Price Target Increase: The average one-year price target for Sera Prognostics has been revised to $5.10 per share, reflecting an 81.82% increase from the previous estimate of $2.80.
Fund Sentiment: There are currently 104 funds reporting positions in Sera Prognostics, a decrease of 31.13% from the last quarter, with total shares owned by institutions down by 8.98%.
Shareholder Activity: Key shareholders include Baker Bros. Advisors and Whetstone Capital Advisors, with no changes in their holdings, while Standard Life Aberdeen decreased its allocation by 42.64% and Tekla Healthcare Opportunities Fund increased its holdings by 51.74%.
Market Outlook: The put/call ratio for Sera Prognostics is 0.28, indicating a bullish sentiment among investors.
Sera Prognostics (SERA) Receives Upgrade to Buy: Reasons Explained
Sera Prognostics Upgrade: Sera Prognostics, Inc. has been upgraded to a Zacks Rank #2 (Buy) due to a positive shift in earnings estimates, indicating a favorable outlook for the company's stock price.
Earnings Estimate Revisions: The Zacks rating system, which correlates earnings estimate revisions with stock price movements, suggests that Sera's rising estimates reflect an improvement in its underlying business, likely leading to higher stock performance.
Zacks Rank System: The Zacks Rank system classifies stocks based on earnings estimates, with only the top 20% receiving a "Strong Buy" or "Buy" rating, highlighting Sera's strong position among its peers.
AI Investment Opportunities: The article also discusses the potential for significant wealth creation in the next phase of AI development, suggesting that early investors in emerging companies may benefit from substantial gains.
Sera Prognostics to Announce Q4 and FY 2025 Financial Results
- Earnings Release Schedule: Sera Prognostics will report its Q4 and FY 2025 financial results on March 18, 2026, after market close, which is expected to positively influence investor confidence.
- Conference Call Details: The company will host a conference call at 5:00 PM ET on the same day to discuss financial results and operational highlights, enhancing transparency and attracting more investor interest.
- Innovative Testing Product: Sera's PreTRM® Test is the only broadly validated blood-based biomarker test that provides early, individualized risk predictions for spontaneous preterm birth during weeks 18 to 20 of pregnancy, enabling more informed clinical decisions by physicians.
- Market Demand Context: The 2025 March of Dimes report indicates persistent poor preterm birth rates in the U.S., affecting newborn health, and Sera's products are poised to improve this situation by providing early intervention information, potentially reducing healthcare costs.
Sera Prognostics to Present at TD Cowen Health Care Conference
- Conference Participation: Sera Prognostics will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, in Boston, showcasing the company's latest achievements, which is expected to attract investor attention and enhance the company's market image.
- Innovative Testing: The company's PreTRM® Test is the only broadly validated blood-based biomarker test that predicts the risk of spontaneous preterm birth during weeks 18 to 20 of pregnancy, enabling physicians to make more personalized clinical decisions and improve maternal and neonatal health management.
- Preterm Birth Issue: According to the 2025 March of Dimes Report, the U.S. received a D+ grade for preterm birth for the fourth consecutive year, highlighting the long-term challenges in improving preterm birth rates, with healthcare costs associated with prematurity estimated at $25 billion in 2016, imposing a significant economic burden on society.
- Future Outlook: Sera Prognostics' participation not only demonstrates its leadership in maternal and neonatal health but may also enhance the market acceptance of the PreTRM Test, driving future revenue growth and capital management needs.
Sera Prognostics Launches New Blood Test Significantly Reducing Preterm Birth Risk
- Preterm Risk Screening: The PRIME study demonstrates that among 5,018 women, those identified as high-risk through the PreTRM Test and receiving targeted interventions significantly reduced preterm birth risks and improved neonatal outcomes, highlighting the test's effectiveness in early identification of at-risk pregnancies.
- Intervention Effectiveness: By administering daily vaginal progesterone and low-dose aspirin, the study found that women using the PreTRM Test had a significantly lower NICU admission rate compared to standard care, with approximately 39 women needing to be screened to prevent a single NICU admission.
- Strengthening Clinical Evidence: Zhenya Lindgardt, CEO of Sera Prognostics, noted that the findings not only reinforce the strong results from the AVERT PRETERM Trial but also build a robust clinical evidence base for the PreTRM test-and-treat strategy, driving transformation in maternal and neonatal health.
- Future Outlook: Sera Prognostics aims to enhance maternal and neonatal health outcomes through education and equitable access to prenatal care, anticipating measurable value for patients, providers, and health systems while setting a new commercial and clinical standard.
Biotech Stocks Decline, Sera Prognostics Falls 10.1%
- Market Underperformance: Biotechnology stocks collectively declined by approximately 1.1%, indicating the sector's vulnerability in the current market environment, which could negatively impact investor confidence and lead to capital outflows.
- Individual Stock Drag: Sera Prognostics saw a significant drop of about 10.1%, while Rezolute fell approximately 9.1%, raising concerns about the overall biotech sector and potentially affecting the fundraising capabilities of related companies.
- Industry Trends: The overall weakness in the biotech sector may reflect investor caution regarding the progress of new drug developments, particularly amid increasing economic uncertainties, which could lead to reduced investments within the industry.
- Market Sentiment Impact: As biotech stocks decline, market sentiment may further deteriorate, prompting investors to reassess their investment strategies in the sector, which could affect future capital inflows.
Sera Prognostics (SERA) Price Target Raised by 81.82% to $5.10
Price Target Increase: The average one-year price target for Sera Prognostics has been revised to $5.10 per share, reflecting an 81.82% increase from the previous estimate of $2.80.
Fund Sentiment: There are currently 104 funds reporting positions in Sera Prognostics, a decrease of 31.13% from the last quarter, with total shares owned by institutions down by 8.98%.
Shareholder Activity: Key shareholders include Baker Bros. Advisors and Whetstone Capital Advisors, with no changes in their holdings, while Standard Life Aberdeen decreased its allocation by 42.64% and Tekla Healthcare Opportunities Fund increased its holdings by 51.74%.
Market Outlook: The put/call ratio for Sera Prognostics is 0.28, indicating a bullish sentiment among investors.
Sera Prognostics (SERA) Receives Upgrade to Buy: Reasons Explained
Sera Prognostics Upgrade: Sera Prognostics, Inc. has been upgraded to a Zacks Rank #2 (Buy) due to a positive shift in earnings estimates, indicating a favorable outlook for the company's stock price.
Earnings Estimate Revisions: The Zacks rating system, which correlates earnings estimate revisions with stock price movements, suggests that Sera's rising estimates reflect an improvement in its underlying business, likely leading to higher stock performance.
Zacks Rank System: The Zacks Rank system classifies stocks based on earnings estimates, with only the top 20% receiving a "Strong Buy" or "Buy" rating, highlighting Sera's strong position among its peers.
AI Investment Opportunities: The article also discusses the potential for significant wealth creation in the next phase of AI development, suggesting that early investors in emerging companies may benefit from substantial gains.
